Bio-Rad Laboratories, Inc. Class A Common Stock (BIO)

Stocks are headed for weekly gains, with the Dow Jones dipping slightly and the S&P 500 and Nasdaq trading just above the flatline Friday.

History says Palantir stock could soar after its inclusion in the S&P 500.

Palantir (PLTR) stock surges due to inclusion in S&P 500 on Sept. 23 and new enterprise deal with BP. Technicals also show bullish trend.

Palantir, Dell Technologies and Erie Indemnity will join the S&P 500 on Sept. 23. All three stocks jumped late Friday.

The market's resilient run has made traders cautious of a potential correction, but analysts remain optimistic about its trajectory.

Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million.

BIO stock results show that Bio-Rad Laboratories beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024.

480 out of 500 S&P 500 companies are trading below analysts' price targets, indicating potential profit opportunities. April has been bleak for the market, but some undervalued stocks may be worth buying. Top 5 stocks with biggest gap between price and target: CCL, BIO, WBD, CZR, CCO.

Wall Street takes pause after stronger-than-expected producer inflation report, potentially delaying Fed rate cuts and impacting major indices and stocks.

U.S. stocks were lower, with the Dow Jones index falling more than 100 points on Friday.

S&P 500 index surges to new highs, driven by AI, earnings optimism, and Fed rate cuts. Top 10 stocks with significant upside potential for 2024 rally.

Fifty-six percent of S&P 500 companies have shown positive performance in 2023 and 44% retreated Moderna Inc. (NASDAQ: MRNA) offers the highest upside potential (58%).

Several S&P 500 stocks are trading at discounts of over 40% compared to analysts' price targets, offering potential upside, but caution is needed.

Bio-Rad Laboratories Inc (NYSE: BIO) shares are trading lower after the company lowered its annual revenue growth forecast, citing the uncertain pace of the biopharma sector's recovery and the